- Type of Event: Q2 FY27 Earnings Conference Call hosted by Elara Securities Private Limited
- Date and Time: Wednesday, 4th November 2026 (time not specified)
- Purpose: Discussion of quarterly results and strategic update for the second quarter and half year ended September 30, 2026
- Management Participants: Mr. D. Ram Reddy – Managing Director of Balaji Amines Limited
- Moderator: Mr. Akshat Vijay – Elara Securities Private Limited
- Availability of Materials: The transcript, financial results, press release, and investor presentation were uploaded on stock exchanges and the company website at https://www.balajiamines.com/investor-relations.php
- Compliance Statement: The disclosure is made pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Financial Performance Highlights:
- Q2 FY27 Consolidated Revenue: INR472 crores (vs. INR348 crores in Q2 FY26, +36% YoY)
- Q2 FY27 Consolidated EBITDA: INR106 crores (vs. INR67 crores in Q2 FY26, +58% YoY)
- Q2 FY27 EBITDA Margin: 22% (vs. 19% in Q2 FY26)
- Q2 FY27 PAT: INR67 crores (vs. INR37 crores in Q2 FY26, +82% YoY)
- Q2 FY27 Diluted EPS: INR20.76 per equity share (vs. INR10.67 in Q2 FY26)
- H1 FY27 Consolidated Revenue: INR933 crores (vs. INR715 crores in H1 FY26, +31% YoY)
- H1 FY27 Consolidated EBITDA: INR227 crores (vs. INR131 crores in H1 FY26, +74% YoY)
- H1 FY27 EBITDA Margin: 24% (vs. 18% in H1 FY26)
- H1 FY27 PAT: INR146 crores (vs. INR74 crores in H1 FY26, +98% YoY)
Operational Performance:
- Q2 FY27 Sales Volumes: 24,491 metric tons (vs. 26,165 metric tons in Q2 FY26, -6% YoY; vs. 21,587 metric tons in Q1 FY27, +13.5% QoQ)
- Segment-wise Q2 Volumes: Amines (6,525 MT), Amines Derivatives (8,974 MT), Specialty Chemicals (8,992 MT)
- H1 FY27 Sales Volume: 46,078 metric tons (vs. 53,735 metric tons in H1 FY26)
Expansion Updates:
- Acetonitrile Plant: Commenced commercial production with expanded capacity of 1,440 tons per month
- DME Plant: Received PESO Nagpur office approval for Road Tanker valves after thorough testing process
- N-Methyl Morpholine (NMM): Project progressing, targeted for commercialization during FY27
- Balaji Specialty Chemicals Unit-1: Brownfield expansion for EDA-based derivatives (DETA, TETA, Piperazine, AEEA, AEP) expected commissioning end of FY27
- Balaji Specialty Chemicals Unit-2: Greenfield expansion at MIDC, Chincholi for hydrogen cyanide, sodium cyanide, EDTA and EDTA-2Na targeted for Q4 FY27 commissioning
Balance Sheet Position (as of September 30, 2026):
- Consolidated Net Worth: INR2,083.02 crores (corrected from INR2,023.02 crores mentioned during call)
- Consolidated Debt: INR161.15 crores
- Cash and Cash Equivalents: INR52.62 crores
- H1 FY27 Cash Flow from Operations: INR54.46 crores
- H1 FY27 Capital Expenditure: INR99.38 crores
- Standalone Position: Zero debt
Additional Notes:
- The document includes the full transcript of the earnings conference call with Q&A session
- Multiple analysts from firms including Alpha Invesco, HDFC Securities, Scientific Investing, and private investors participated in the Q&A
- Key discussion topics included DMF plant utilization, DMC contracts with battery electrolyte manufacturers, EDA antidumping case, DME approvals for LPG blending, and raw material price volatility
- Management expressed confidence in achieving INR3,500-4,000 crores revenue by FY28-29 based on current expansion pipeline
- The company emphasized focus on improving capacity utilization, commercialization of new products, and enhancing customer base for expanded facilities